This is a summary of the European public assessment report (EPAR) for Eurartesim. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Eurartesim.
Therapeutic Indication
### Therapeutic indication Eurartesim is indicated for the treatment of uncomplicated Plasmodium falciparum malaria in adults, children and infants 6 months and over and weighing 5 kg or more. Consideration should be given to official guidance on the appropriate use of antimalarial agents.
Therapeutic Area (MeSH)
ATC Code
P01BF05
ATC Item
artenimol and piperaquine
Pharmacotherapeutic Group
Antiprotozoals
Active Substance (Summary)
INN / Common Names
EMA Name
Eurartesim
Medicine Name
Eurartesim
Aliases
N/ANo risk management plan link.
